M Zhang1, C Guo1, Y Chu1, R Xu1, F Yin1, J Qian1. 1. Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu 233000, China.
Abstract
OBJECTIVE: To explore the effect of dihydromyricetin on the expression of miR-98-5p and its mechanism in the development of Herceptin resistance in SKBR3 cells. METHODS: The expression of IGF2 and miR-98-5p and their interaction relationship were analyzed by bioinformatics analysis through TargetScan online databases. SKBR3 cells and drug-resistant SKBR3-R cells were cultured in cell experiments. Xenograft tumor mice were constructed by SKBR3 and SKBR3-R cells. Proteins were detected by western blotting and immunohistochemistry. Transfected cells were constructed by shRNA lentivirus vectors. RT-QPCR was used to detect RNA. Cell proliferation was detected by MTS method. Cell jnvasion was detected by Transwell assay. Luciferase reporting assays were used to verify RNA interactions. IGF-1R/HER2 heterodimer was determined by immunocoprecipitation. RESULTS: The expression of IGF2, p-IGF1R, p-Akt and p-S6K in SKBR3-R cells were significantly higher than those in SKBR3 cells, while the expression of PTEN protein was lower in SKBR3-R cells (P < 0.05). IGF1R/HER2 heterodimer in SKBR3-R cells was significantly increased (P < 0.01).The expression of IGF2 and invasion ability were significantly reduced while transfected with miR-98-5p in SKBR3-R cells (P < 0.05), but the IGF2 mRNA were no difference in both cells (P > 0.05). The expression of miR-98-5p was up-regulated and IGF2 was decreased in drug-resistant xenograft tumor mice after feeding with dihydromyricetin, and the tumor became more sensitivity to Herceptin (P < 0.05). CONCLUSION: Dihydromyricetin could induce the expression of miR-98-5p, which binds to IGF2 mRNA to reduce IGF2 expression, inhibit the IGF-1R/HER2 formation, thereby reversing cell resistance to Herceptin in SKBR3-R cells.
OBJECTIVE: To explore the effect of dihydromyricetin on the expression of miR-98-5p and its mechanism in the development of Herceptin resistance in SKBR3 cells. METHODS: The expression of IGF2 and miR-98-5p and their interaction relationship were analyzed by bioinformatics analysis through TargetScan online databases. SKBR3 cells and drug-resistant SKBR3-R cells were cultured in cell experiments. Xenograft tumor mice were constructed by SKBR3 and SKBR3-R cells. Proteins were detected by western blotting and immunohistochemistry. Transfected cells were constructed by shRNA lentivirus vectors. RT-QPCR was used to detect RNA. Cell proliferation was detected by MTS method. Cell jnvasion was detected by Transwell assay. Luciferase reporting assays were used to verify RNA interactions. IGF-1R/HER2 heterodimer was determined by immunocoprecipitation. RESULTS: The expression of IGF2, p-IGF1R, p-Akt and p-S6K in SKBR3-R cells were significantly higher than those in SKBR3 cells, while the expression of PTEN protein was lower in SKBR3-R cells (P < 0.05). IGF1R/HER2 heterodimer in SKBR3-R cells was significantly increased (P < 0.01).The expression of IGF2 and invasion ability were significantly reduced while transfected with miR-98-5p in SKBR3-R cells (P < 0.05), but the IGF2 mRNA were no difference in both cells (P > 0.05). The expression of miR-98-5p was up-regulated and IGF2 was decreased in drug-resistant xenograft tumor mice after feeding with dihydromyricetin, and the tumor became more sensitivity to Herceptin (P < 0.05). CONCLUSION: Dihydromyricetin could induce the expression of miR-98-5p, which binds to IGF2 mRNA to reduce IGF2 expression, inhibit the IGF-1R/HER2 formation, thereby reversing cell resistance to Herceptin in SKBR3-R cells.
Entities:
Keywords:
Herceptin; breast cancer; dihydromyricetin; drug resistance; heterodimer; miR-98-5p
Authors: Ching-yi Chang; Dmitri Kazmin; Jeff S Jasper; Rebecca Kunder; William J Zuercher; Donald P McDonnell Journal: Cancer Cell Date: 2011-10-18 Impact factor: 31.743
Authors: Gal Lenz; Angelica Hamilton; Shuhui Geng; Teresa Hong; Markus Kalkum; Jamil Momand; Susan E Kane; Janice M Huss Journal: Clin Cancer Res Date: 2017-11-27 Impact factor: 12.531
Authors: Brigid C Browne; Alex J Eustace; Susan Kennedy; Neil A O'Brien; Kasper Pedersen; Martina S J McDermott; Annemarie Larkin; Jo Ballot; Thamir Mahgoub; Francesco Sclafani; Stephen Madden; John Kennedy; Michael J Duffy; John Crown; Norma O'Donovan Journal: Breast Cancer Res Treat Date: 2012-11-02 Impact factor: 4.872
Authors: A Gallardo; E Lerma; D Escuin; A Tibau; J Muñoz; B Ojeda; A Barnadas; E Adrover; L Sánchez-Tejada; D Giner; F Ortiz-Martínez; G Peiró Journal: Br J Cancer Date: 2012-03-27 Impact factor: 7.640
Authors: Kinga Molnár; Ádám Mészáros; Csilla Fazakas; Mihály Kozma; Fanni Győri; Zita Reisz; László Tiszlavicz; Attila E Farkas; Ádám Nyúl-Tóth; János Haskó; István A Krizbai; Imola Wilhelm Journal: Mol Oncol Date: 2020-06-26 Impact factor: 6.603